Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) and Sapu Bioscience today announced key advancements in its global intellectual...
January 21, 2026 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
December 15, 2025 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
November 20, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
October 23, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Radiopharmaceutical CDMO Market Size/Share Worth USD 7.2 Billion by 2034 at a 9.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Radiopharmaceutical CDMO Market Size, Trends and Insights By Application...
August 21, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biologics and Biosimilars Market Size, Trends and Insights By Product Type...
August 13, 2025 06:00 ET | Source: Neuronascent, Inc.

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its...
July 24, 2025 15:30 ET | Source: Custom Market Insights

[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and...
April 10, 2025 09:12 ET | Source: Albatroz Therapeutics

Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May Reverse Disease Progression

Nature study uncovers insights about the progression of osteoarthritis (OA) and rheumatoid arthritis; demonstrates therapeutic approach targeting Calnexin.
March 26, 2025 15:00 ET | Source: Custom Market Insights

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, March 27, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme...